Eng, Stefan E. http://orcid.org/0000-0002-5245-6507
Basasie, Benjamin
Lam, Alfonso
John Semmes, O.
Troyer, Dean A.
Clarke, Geoffrey D. http://orcid.org/0000-0003-4559-6437
Sunnapwar, Abhijit G.
Leach, Robin J.
Johnson-Pais, Teresa L.
Sokoll, Lori J. http://orcid.org/0000-0001-5130-0060
Chan, Daniel W.
Tosoian, Jeffrey J.
Siddiqui, Javed
Chinnaiyan, Arul M.
Thompson, Ian M. Jr.
Boutros, Paul C. http://orcid.org/0000-0003-0553-7520
Liss, Michael A. http://orcid.org/0000-0001-6978-1026
Funding for this research was provided by:
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-15-1-0441)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA086368, P30CA054174, P30CA016042)
Division of Cancer Prevention, National Cancer Institute (U01CA214194, U24CA115102, U01CA214170)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
SPORE Career Enhancement Program
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 25 April 2022
Revised: 10 August 2022
Accepted: 24 August 2022
First Online: 12 September 2022
Competing interests
: JJT and AMC are co-founders and have equity in Lynx Dx, which has licensed the urine biomarkers mentioned in this study from Hologic and the University of Michigan. JJT has leadership roles in Lynx Dx. The University of Michigan has been issued a patent on ETS gene fusions in prostate cancer on which AMC is a co-inventor.